New drug ENERGI-F705 takes first step: safety check in 24 volunteers
NCT ID NCT07650383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the safety and tolerability of a single dose of ENERGI-F705 tablets in 24 healthy adults aged 18 to 44. Participants were randomly assigned to receive either a 60 mg or 120 mg dose of the drug or a placebo (vehicle control). The study measured side effects and how the drug moves through the body, but it was not designed to test any treatment effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ENERGI-F705 tablets
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH ADULT SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Medical University Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can the right work-rest rhythm and a massage gun soften stiff calf muscles?
- Beetroot boost: does more nitrate mean more endurance?
- What makes people move? new study probes the secrets of physical activity
- New daily pill TIX100 takes first step toward tackling obesity
- New skin ointment takes first step toward treating inflammatory conditions
- One yoga session may boost heart health overnight